Drug Search Results
More Filters [+]

Motixafortide

Alternative Names: motixafortide, bl-8040, bl8040, bl 8040, Aphexda
Latest Update: 2024-06-04
Latest Update Note: Clinical Trial Update

Product Description

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies. (Sourced from: https://www.biolinerx.com/pipeline/bl-8040/overview)

Mechanisms of Action: CXCR4 Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: Orphan Drug - Pancreatic Cancer *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BioLineRx
Company Location: MODI-IN L3 7177871
Company CEO:
Additonal Commercial Interests: GenFleet Therapeutics (Australia)

Clinical Description

Map of Global Clinical Trials for Motixafortide

Countries in Clinic: Germany, Hungary, Israel, Italy, Japan, Korea, Spain, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Multiple Myeloma

Phase 2: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Pancreatic Cancer

Phase 1: Anemia, Sickle Cell|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SCDSTEMM

P1

Not yet recruiting

Anemia, Sickle Cell

2026-01-01

NCT05618301

P1

Recruiting

Anemia, Sickle Cell

2025-12-31

Morpheus-Pancreatic Cancer

P2

Active, not recruiting

Pancreatic Cancer|Adenocarcinoma

2025-10-31

45%

Morpheus-Pancreatic Cancer

P2

Active, not recruiting

Pancreatic Cancer|Adenocarcinoma

2025-10-31

45%

Morpheus-Pancreatic Cancer

P2

Active, not recruiting

Pancreatic Cancer|Adenocarcinoma

2025-10-31

45%

Morpheus-Pancreatic Cancer

P2

Active, not recruiting

Pancreatic Cancer|Adenocarcinoma

2025-10-31

45%

AAAS9513

P2

Recruiting

Pancreatic Cancer|Adenocarcinoma

2025-07-01

Recent News Events